IHT Wealth Management LLC Lowers Stock Position in Zoetis Inc. (NYSE:ZTS)

IHT Wealth Management LLC decreased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 44.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,517 shares of the company's stock after selling 1,997 shares during the quarter. IHT Wealth Management LLC's holdings in Zoetis were worth $410,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Soros Capital Management LLC boosted its position in shares of Zoetis by 82.4% during the 4th quarter. Soros Capital Management LLC now owns 13,211 shares of the company's stock valued at $2,152,000 after purchasing an additional 5,970 shares in the last quarter. Fayez Sarofim & Co boosted its position in shares of Zoetis by 13.9% during the 4th quarter. Fayez Sarofim & Co now owns 1,174,143 shares of the company's stock valued at $191,303,000 after purchasing an additional 143,225 shares in the last quarter. Van Lanschot Kempen Investment Management N.V. boosted its position in shares of Zoetis by 48.7% during the 4th quarter. Van Lanschot Kempen Investment Management N.V. now owns 169,939 shares of the company's stock valued at $27,688,000 after purchasing an additional 55,621 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Zoetis by 103.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 23,979 shares of the company's stock valued at $3,907,000 after purchasing an additional 12,178 shares in the last quarter. Finally, Mirova boosted its position in shares of Zoetis by 76.1% during the 4th quarter. Mirova now owns 31,570 shares of the company's stock valued at $5,144,000 after purchasing an additional 13,641 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock valued at $312,254 over the last three months. Company insiders own 0.16% of the company's stock.

Zoetis Stock Performance

Shares of ZTS traded down $0.68 on Thursday, reaching $155.72. 1,909,777 shares of the company's stock traded hands, compared to its average volume of 2,994,977. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock's 50 day simple moving average is $158.73 and its two-hundred day simple moving average is $167.90. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The stock has a market cap of $69.48 billion, a PE ratio of 28.47, a PEG ratio of 2.78 and a beta of 0.92.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. On average, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's payout ratio is currently 36.56%.

Analysts Set New Price Targets

ZTS has been the topic of several research analyst reports. Piper Sandler upped their target price on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. Morgan Stanley cut their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Stifel Nicolaus cut their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Finally, Barclays increased their price target on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $214.40.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.